TYK2 and viral infectious disease: Second-generation JAKi, such as filgotinib, itacitinib, and upadacitinib (anti JAK1), fedratinib (anti JAK2), and deucravacitinib (anti TYK2) offer greater target specificity and may provide a lower risk for hematological abnormalities and viral infections.